Aims To assess the proportion of patients with heart failure and reduced ejection fraction (HFrEF) who are eligible for sacubitril/valsartan (LCZ696) based on the European Medicines Agency/Food and Drug Administration (EMA/FDA) label, the PARADIGM‐HF trial and the 2016 ESC guidelines, and the association between eligibility and outcomes. Methods and results Outpatients with HFrEF in the ESC‐EORP‐HFA Long‐Term Heart Failure (HF‐LT) Registry between March 2011 and November 2013 were considered. Criteria for LCZ696 based on EMA/FDA label, PARADIGM‐HF and ESC guidelines were applied. Of 5443 patients, 2197 and 2373 had complete information for trial and guideline eligibility assessment, and 84%, 12% and 12% met EMA/FDA label, PARADIGM‐HF and guideline criteria, respectively. Absent PARADIGM‐HF criteria were low natriuretic peptides (21%), hyperkalemia (4%), hypotension (7%) and sub‐optimal pharmacotherapy (74%); absent Guidelines criteria were LVEF>35% (23%), insufficient NP levels (30%) and sub‐optimal pharmacotherapy (82%); absent label criteria were absence of symptoms (New York Heart Association class I). When a daily requirement of ACEi/ARB ≥ 10 mg enalapril (instead of ≥ 20 mg) was used, eligibility rose from 12% to 28% based on both PARADIGM‐HF and guidelines. One‐year heart failure hospitalization was higher (12% and 17% vs. 12%) and all‐cause mortality lower (5.3% and 6.5% vs. 7.7%) in registry eligible patients compared to the enalapril arm of PARADIGM‐HF. Conclusions Among outpatients with HFrEF in the ESC‐EORP‐HFA HF‐LT Registry, 84% met label criteria, while only 12% and 28% met PARADIGM‐HF and guideline criteria for LCZ696 if requiring ≥ 20 mg and ≥ 10 mg enalapril, respectively. Registry patients eligible for LCZ696 had greater heart failure hospitalization but lower mortality rates than the PARADIGM‐HF enalapril group.

No abstract

No abstract

Myxomas are the most common type of benign cardiac tumor. The most frequent clinical presentations are symptoms resulting from atrioventricular valve obstruction or systemic embolization. Coronary embolization is a rare, although real and potentially fatal, complication of cardiac myxomas. We present a case report and review of the literature on this disease association. A 57-year-old woman was admitted to our coronary care unit with a diagnosis of non-ST elevation acute myocardial infarction. Transthoracic echocardiography showed a large left atrial mass attached to the interatrial septum, coral-like and with a friable appearance, suggestive of myxoma. Coronary angiography revealed no significant lesions and the patient underwent surgical excision of the mass, which histological study showed to be compatible with myxoma. The postoperative period was uneventful and the patient is doing well, with no recurrence of myxoma.

Constrictive pericarditis is a clinical condition characterized by the appearance of signs and symptoms of right heart failure due to loss of pericardial compliance. Cardiac surgery is now one of the most frequent causes in developed countries, while tuberculosis remains the most prevalent cause in developing countries. Malignancy is a rare cause but usually has a poor prognosis. The diagnosis of constrictive pericarditis remains a clinical challenge and requires a combination of noninvasive diagnostic methods (echocardiography, cardiac magnetic resonance and computed tomography); in some cases, cardiac catheterization is needed to confirm the diagnosis. The authors present the case of a 51-year-old man, hospitalized due to cardiac tamponade. Diagnostic investigation was suggestive of tuberculous etiology. Despite directed medical therapy, the patient developed effusive-constrictive physiology. He underwent pericardiectomy and anatomopathologic study suggested a neoplastic etiology. The patient died in the postoperative period from biventricular failure. Pericardite efusiva-constritiva; Insuficiência cardíaca; Ecocardiografia; Pericardite efusiva-constritiva como manifestação de um diagnóstico inesperadoResumo A pericardite constritiva é uma entidade clínica caracterizada pelo aparecimento de sinais e sintomas de insuficiência cardíaca direita, secundários à perda da compliance pericárdica. Atualmente, a cirurgia cardíaca tornou-se numa das etiologias mais frequentes nos países desenvolvidos, mantendo-se a tuberculose como a causa mais prevalente nos países em vias de desenvolvimento. As etiologias neoplásicas são mais raras e habitualmente de pior ଝ Please cite this article as: Marta L, Alves M, Peres M, et al. Pericardite efusiva-constritiva como manifestação de um diagnóstico inesperado. Rev Port Cardiol. 2014. http://dx.69.e2 L. Marta et al. Ressonância magnética cardíaca; Diagnóstico prognóstico. O diagnóstico desta entidade mantém-se um desafio clínico, sendo necessária a integração dos achados dos métodos de diagnóstico não invasivos (ecocardiografia, ressonância magnética e tomografia computorizada) e por vezes o recurso ao cateterismo cardíaco. Os autores apresentam o caso clínico de um homem de 51 anos de idade, internado por tamponamento cardíaco. A investigação etiológica foi sugestiva de etiologia tuberculosa, que apesar da terapêutica médica dirigida, evoluiu para fisiologia efusiva-constritiva. Foi submetido a pericardiectomia e o exame anátomo-patológico sugeriu etiologia neoplásica. O doente veio a falecer no pós-operatório em falência biventricular.